+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 55 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
R

Actively Recruiting

Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.

Age: 18Years +All GendersPhase 3
163 locations
E

Actively Recruiting

Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.

Age: 18Years - 130YearsAll GendersPhase 3
89 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of targeted therapies and immunotherapy, either alone or in combination, for patients with metastatic colorectal cancer mCRC whose tumors test positive for specific biomarkers. This open-label, Phase 11b study enrolls participants into different treatment groups based on their biomarker test results to explore personalized treatment approaches. Participants receive various combinations of study drugs, including oral medications like inavolisib and divarasib and intravenous infusions such as cetuximab, bevacizumab, atezolizumab, tiragolumab, SY-5609, FOLFOX, and FOLFIRI chemotherapy. Treatment cycles vary from 21 to 28 days depending on the assigned treatment arm, with dosing schedules including daily oral medications and infusions given weekly, every two weeks, or every three weeks. Some treatment arms are closed or not recruiting, while others remain active. Throughout the study, participants undergo regular assessments including tumor imaging to measure response, blood tests, and biomarker sampling. Researchers monitor outcomes such as objective response rate, disease control, duration of response, and adverse events over approximately 84 months. Participants overall health and tumor status are closely followed to evaluate treatment effects and safety during and after therapy.

Age: 18Years +All GendersPhase 1
84 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combination of two investigational drugs, avutometinib and defactinib, compared to standard treatments chosen by doctors in patients with recurrent low-grade serous ovarian cancer LGSOC who have progressed after prior platinum-based therapy. This Phase 3, international, randomized, open-label study aims to compare progression-free survival and also assess overall survival, safety, quality of life, and disease symptoms. The study is conducted by specialists in gynecological cancer. Participants will receive either the combination of avutometinib and defactinib or one of four standard treatments recommended for recurrent LGSOC. Avutometinib is given orally at 3.2 mg twice weekly for 21 days followed by 7 days off in a 28-day cycle, combined with defactinib given orally at 200 mg twice daily on the same schedule. The standard treatments include pegylated liposomal doxorubicin, paclitaxel, anastrozole, or letrozole, each administered according to their usual dosing schedules. Patients initially receiving standard treatment who experience disease progression may switch to the investigational drug combination. During the study, participants will have regular visits for treatment and follow-up assessments including laboratory tests and evaluations of tumor status. Researchers will monitor progression-free survival for up to 24 months and overall survival for up to 5 years. They will also assess response rates, duration of response, disease control, adverse events, blood drug levels, and quality of life using questionnaires. The total study duration may extend until 2031, with ongoing monitoring of health and symptoms throughout.

Age: 18Years +FEMALEPhase 3
105 locations
P

Actively Recruiting

This trial is a Phase 2 study evaluating axatilimab, an antibody targeting the colony stimulating factor 1 receptor, in participants aged 2 years and older with recurrent or refractory active chronic graft versus host disease cGVHD. These participants have previously received at least two lines of systemic therapy but still have active disease requiring further treatment. The study aims to assess the efficacy, safety, and tolerability of axatilimab at different dose levels in this population. Participants will be randomly assigned to one of three axatilimab dosing regimens administered intravenously. The doses include 0.3 mgkg every two weeks, 1 mgkg every two weeks, or 3 mgkg every four weeks. Treatment cycles last 28 days and may continue for up to two years. This open-label, multicenter study allows participants to receive axatilimab while being closely monitored. During the study, participants will have regular assessments to evaluate treatment response based on established NIH criteria for cGVHD. Researchers will measure overall response rates in the first six cycles as well as throughout the study period of up to two years. Other evaluations include symptom scales, organ-specific responses, medication use changes, laboratory biomarkers, and safety monitoring. Participants are followed for efficacy, tolerability, and adverse events during treatment and for the full study duration.

Age: 2Years +All GendersPhase 2
121 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a chemotherapy payload, compared to treatment chosen by physicians including paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine for patients with first-line metastatic triple-negative breast cancer TNBC or low estrogen receptor ER-low, HER2-negative breast cancer who cannot receive anti-PDL1 or endocrine therapies. This study includes adults with locally advanced, recurrent inoperable, or metastatic disease who meet specific eligibility criteria. Participants are randomly assigned to receive iza-bren or one of the physicians choice chemotherapy regimens. The treatments are given at specified doses on scheduled days. The study includes two phases Phase 2 to determine the recommended dose of iza-bren and Phase 3 to compare progression-free survival and other outcomes. The study will last several years, with follow-up extending up to approximately 47 months after randomization. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests, and monitoring for adverse events. Quality of life questionnaires will also be completed. Researchers will track progression-free survival, overall survival, treatment-related side effects, tumor size changes, and patient-reported outcomes to evaluate the treatments. The total participation duration may extend up to several years depending on treatment response and follow-up requirements.

Age: 18Years +All GendersPhase 2Phase 3
295 locations
S

Actively Recruiting

Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.

Age: 18Years +All GendersPhase 3
364 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, and efficacy of zedoresertib combined with temozolomide TMZ, with or without radiotherapy RT, in adults with glioblastoma GBM. This study includes a Phase 1 dose escalation to identify dose-limiting toxicities and a dose expansion to find the recommended dose. Phase 2 will assess the effectiveness of zedoresertib at this dose combined with TMZ compared to standard treatment in adults with GBM. Participants in different study arms receive intermittent escalating doses of zedoresertib capsules combined with TMZ capsules in 28-day cycles for up to two years, or combined with TMZ and RT for up to six weeks. Phase 1 includes three arms, but Arm B involving RT has been permanently halted for safety reasons. Phase 2 will start after determining the recommended dose from Phase 1 and will focus on zedoresertib plus TMZ treatment. During the study, participants will have regular visits for treatment and monitoring. Researchers will assess dose-limiting toxicities, adverse events, laboratory tests, heart function tests ECG and echocardiogram, and performance status. Tumor size will be measured by MRI using RANO criteria. Pharmacokinetics and pharmacodynamics will be evaluated through blood samples. Survival and disease progression will be tracked up to approximately 66 months. Safety will be monitored up to 30 days after treatment ends.

Age: 18Years +All GendersPhase 1Phase 2
16 locations
E

Actively Recruiting

Researchers are evaluating the safety and changes in disease activity of different treatment combinations using mirvetuximab soravtansine with carboplatin, bevacizumab, or bevacizumab alone in adult women with ovarian cancer. This phase 2 study focuses on participants confirmed to have folate receptor alpha positive tumors through a specific assay. The purpose is to assess adverse events and treatment responses across multiple treatment groups. Participants will be assigned to one of three substudies, each with different treatment arms. Treatments involve intravenous infusions of mirvetuximab soravtansine combined with bevacizumab, carboplatin, or both, with dosing variations and sequences depending on the substudy. The study duration varies from approximately 31 to 40 months based on the treatment group and includes follow-up after initial combination therapies. During the study, participants will attend regular hospital or clinic visits for medical assessments including blood tests and scans. Researchers will monitor treatment-emergent adverse events, ocular adverse events, peripheral neuropathy, lung disease, and overall and progression-free survival using standardized criteria. The safety and effectiveness of the treatments will be tracked over the entire study period, which may require a higher treatment burden than standard care.

Age: 18Years +FEMALEPhase 2
86 locations

1-10 of 55

1